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Abstract 
Biomaterials are continually being designed that enable new methods for interacting 
dynamically with cell and tissues, in turn unlocking new capabilities in areas ranging from drug 
delivery to regenerative medicine. In this review we explore some of the recent advances being made 
to in regards to programming biomaterials for improved drug delivery, with a focus on cancer and 
infection. We begin by explaining several of the underlying concepts that are being used to design 
this new wave of drug delivery vehicles, followed by examining recent materials systems that are 
able to coordinate the temporal delivery of multiple therapeutics, dynamically respond to changing 
tissue environments, and reprogram their bioactivity over time. 
Keywords: Bionanoscience, Biomaterials, Drug Delivery, Cancer, Bacteria, 
Nanoparticles   
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1. Introduction 
Diseases such as cancer and infection are many times heterogeneous in nature and exhibit a 
remarkable ability to dynamically adapt to a variety of microenvironments and chemical cues to 
promote proliferation and survival1,2. Cancers often accomplish this through high mutation rates3, 
while bacterial infections develop innate resistance due to repeated sub-lethal challenges or enhance 
their survival through the formation of biofilms4. Treating these conditions commonly involves the 
use of systemic delivery of cytotoxic drugs that target rapidly dividing cells, block specific pathways 
that confer survival benefits, or interfere with bacteria-specific building blocks. While many times 
this basic systemic strategy can be effective, there are associated side effects such as unintended 
targeting of healthy dividing cells, for instance those located in the hair follicles or mucous 
membranes, or killing of beneficial probiotic bacteria. To increase effectiveness while concomitantly 
reducing unwanted side effects, new strategies are being developed for targeted delivery to the 
complete collection of heterogeneous disease locations by taking advantage of common biomarkers 
or features across all sites5,6. Ideally, these delivery strategies not only concentrate delivery in target 
locations, but also preserve bioactivity of sensitive biologic drugs and enable the ability to program 
multi-functional therapeutics, which has frequently been shown to improve patient outcomes7,8. 
In recent years, several biomaterial-based strategies have been developed to tackle these 
challenges. In the context of cancer, many approaches take advantage of the enhanced permeation 
and retention (EPR) effect that leads to accumulation of nanoparticles at the target site due to poorly 
structured vasculature within tumours9. However, these strategies still do not address the complete 
set of aforementioned issues with systemic therapies, target diseases with a static rather than 
potentially more effective temporally coordinated strategy, and typically cannot be tailored to an 
individual patient’s specific disease profile10. 
To address these limitations, recent research is now looking into developing multi-functional 
programmable biomaterials that can address many of the shortcomings of the prior generation of 
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biomaterials. These materials generally exhibit both dynamic and temporal tunability, allowing for 
stimuli-responsive behaviour that can actively adapt to both the progression of the disease and any 
potential changes deemed necessary by the clinician. Furthermore, these platforms are highly 
customizable and allow for a more personalized medicine approach, whether it be choosing which 
drugs to deliver for combinatorial therapy or changing the stimuli-specific responses of the 
biomaterial11. 
In this review, we have outlined some of the widely used approaches and highlighted some of 
the latest advanced therapeutic applications of multi-functional programmable biomaterials. We 
begin by introducing some of the underlying characteristics and behaviour of these enabling 
technologies, specifically oligonucleotide-based nanotechnologies and click chemistries. Afterwards, 
we give several examples of using each enabling technology for applications relating to cancer and 
infectious diseases. Finally, we offer a future outlook and provide potential avenues for new research 
in this rapidly developing field. 
2. Enabling Technologies 
Previous efforts to define programmable materials often look at synergistic and sequential 
drug delivery systems. Synergistic systems require presence of two or more triggers to facilitate drug 
delivery, while sequential systems rely on multiple stimuli to achieve drug release or spur sequential 
drug delivery12. However from a materials point of view, programmability is not limited to these two 
approaches and can be extended to any materials capable of changing their properties over time and 
interacting in a uni- or bi-directional manner with cells. In general, such programmable materials 
consist of multiple modules that can be assembled prior to in vivo administration or refilled once in 
vivo. The first part of this review introduces some of the prominent enabling technologies and 
highlights the advantages and disadvantages of each approach.   
2.1 Delivery Platforms 
5	
	
Two of the most common platforms used to prepare drug delivery systems are nanoparticles 
and hydrogels. Traditionally, nanoparticles have been used to encapsulate and protect drugs, 
concentrate their activity, and improve targeting to tumours9 and sites of infection13; together these 
features work to reduce negative side effects compared to delivery of a free drug14. One advantage of 
using nanoparticles is that they come in a variety of sizes, shapes, chemistries, and stimuli-
responsive elements,15 providing a seemingly countless number of possibilities16,17. This provides a 
diverse palate for designing nanoparticles; for example, the size of a nanoparticle alone can influence 
which organs it will preferentially accumulate in18. Some examples of nanoparticles include 
liposomes for hydrophobic and hydrophilic drug delivery19, Layer-by-Layer-coated particles for 
sustained delivery of therapeutics20, dendrimers for multifunctional therapies21, and gold nanorods 
for optically tunable drug release22.  
On the other hand, hydrogels can be an efficient platform for sustaining the delivery of 
therapeutics over longer periods of time compared to nanoparticles with similar material 
composition23. Their larger size and potential for direct injection via shear thinning24 allows them to 
be placed at a specific location and retain concentrated function locally, in turn reducing systemic 
exposure25.  Since the hydrogel parameters such as degradation rate and swelling are tuneable, they 
can be used as short-term delivery vehicles, stimuli-triggered release platforms26, as well as refillable 
drug depots27. Additionally, it is possible to incorporate combinations of therapeutics that are locally 
activated by various responsive elements28, such as MMP degradable linkers29, enabling on-demand 
and stimuli-specific delivery of therapeutics. Finally, there are multiple methods to adjust the 
properties of hydrogels (e.g. pore size30, stiffness31) as well as ways to incorporate bioactive 
molecules that recruit target cells into the material32 and modify their behaviour.  
While we have highlighted nanoparticles and hydrogels, there are a vast array of possibilities 
not delineated in this review and also other numerous delivery platforms, such as film coatings for 
implants33 and porous membranes for long term delivery34. When considering the appropriate 
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platform from the bevy of options, form follows function and thus the environment, use, and specific 
context should be carefully understood before designing the appropriate delivery system. One of the 
challenges in this regard has been development of fabrication protocols that make it possible to 
reproducibly combine multiple bioactive components on one platform. Commercially available end-
functionalized peptides, nucleic acids, and polymers that can participate in highly efficient and 
biocompatible reactions provides biologically-focused laboratories simple means to develop, test, 
and implement combinatorial approaches both in vitro35 and in vivo36. 
2.2 Click and stimuli-responsive chemistries 
A powerful tool in making materials programmable are click-chemistries, a class of reactions 
that proceed at physiological conditions with high efficiency, rapid reaction kinetics, are bio-
orthogonal, and result in no by-products37. One of the first click-reactions developed is the Cu-
catalyzed azide-alkyne cycloaddition reaction38 (Figure 1a). Unfortunately, difficulty in removing the 
cytotoxic copper ions has precluded its use in many biological applications. In 2007 the Bertozzi 
group overcame this limitation by developing a copper-free bio-orthogonal chemistry for in vivo 
imaging. Their new approach took advantage of the reaction between azides and difluorinated 
cyclooctynes (DIFO) containing ring strain and electron-withdrawing groups39 to replace the Cu 
catalyst. The catalogue of click-chemistries has been continuously expanding since then and it is 
currently possible to perform multiple orthogonal reactions in “one pot” without the need for a 
catalyst37. Importantly, the high biocompatibility of copper-free click reactions enables the labelling 
of not only synthetic materials36 but also cell surfaces40. 
Stimuli-responsive linkers are also particularly useful for introducing programmability into 
drug delivery systems. The first generation of stimuli-responsive materials made use of functional 
groups including hydrazones and disulphides to take advantage of non-specific stimuli such as pH 
and reducing environments, respectively41. Recently, an increasingly popular concept is to 
incorporate groups that are cleaved by specific physical or biological entities such as proteases42 
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(Figure 1c). Depending on the intended application, researchers can optimize the system to be 
cleaved by enzymes located extracellularly, intracellularly, or both. A key challenge in using 
biologically degradable sequences is that it should be highly preferential for cleavage to occur by 
enzymes upregulated specifically within diseased tissues. For example, extracellularly located 
enzymes such as MMPs or hyaluronidase play an important role in turnover of the extracellular 
matrix (ECM), enabling researchers to use such a property to activate systems in vivo29.  
2.3 Oligonucleotides 
Over the past twenty years, DNA/RNA nanotechnology has revolutionised diagnostics, drug 
delivery and intra-cellular as well as extracellular imaging due to, amongst other things, the guiding 
principle of using a simple and well-studied molecule as a building block to develop more complex 
bioactive and versatile systems to control cellular function. In 1996, Tyagi and Kramer developed the 
concept of a molecular beacon43, an approximately 15-30 base-long RNA/DNA sequence consisting 
of an 18-30 base-long loop stabilised by a 5-7 base-pair stem44. This secondary structure is stable 
under ambient or body temperature but can be destabilized by the binding of a complementary 
sequence during the hybridization process, such as during selective interference with mRNA. Both 
the 5’ and 3’ ends of the oligonucleotide can be modified with functional groups such as a 
fluorophore-quencher pair or Förster Resonance Energy Transfer (FRET) pair, which makes it 
possible to simultaneously report on the binding events45. For example, by choosing the loop 
sequence to match mRNA up-regulated in target cells, researchers can down-regulate expression of 
specific genes while simultaneously monitoring the process46.  
Oligonucleotides can also be used as effective drug delivery vehicles47. Like the 
aforementioned FRET pairs, drugs can be covalently conjugated to either end of the oligonucleotide 
as well as to inner bases. Additional drug-delivery approaches make use of the unique molecular 
structure of oligonucleotides. For example, the double stranded stem region of molecular beacons 
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has standard π-π stacking of aromatic rings that are attractive sites for drugs, such as Dox, that 
intercalate the duplex DNA regions48 (Figure 1b).  
Another advantage of oligonucleotides is their ability to bind selected target receptors, 
molecules, and cells with high affinity and specificity, which makes them an ideal component in 
targeted delivery platforms49. This property arises from the tendency of single stranded 
oligonucleotides to fold onto themselves and form thermodynamically favourable secondary 
structures that can be further stabilized by binding appropriate ligands. Sequences that bind to 
desired ligands with sufficient affinity are named aptamers and selected using an in vitro directed 
evolution process called SELEX50,51. The key parameter to take into consideration is the binding 
constant (KD), which is a ratio between the off-rate and on-rate constants. This value should ideally 
lie in at least the nM or pM range to maximize the in vivo efficacy and minimize the required 
dosage52.  
Some of the potential disadvantages of oligonucleotides as a material are their susceptibility 
to degradation by either exonucleases that cut DNA/RNA at the terminal ends or endonucleases that 
cut oligonucleotides within the strand. Because of this, oligonucleotides are frequently attached to 
other molecules, such as polyethylene-glycol (PEG), which blocks exonuclease activity and slows 
renal filtration by increasing molecular weight above the 30-50 kDa molecular mass cutoff of the 
renal glomerulus52. Furthermore, the 2’-OH group on the ribose of RNA nucleotides is frequently 
replaced by molecules such as a 2’Fluoro or 2’O-methyl to increase resistance to degradation by 
endonucleases. Alternatively more stable DNA analogs, such as locked nucleic acids (LNA)53 and 
peptide nucleic acid (PNAs)54 can be used, however the hydrophobicity of PNAs presents unique 
challenges for use in vivo. Finally it is critical to ensure there is no unintended priming of the 
immune system by excessive extracellular RNA or DNA, which in some cases can mimic conditions 
found during infection55. 
3. Recent in vitro and in vivo applications 
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In the subsequent sections of this review, we focus on recent developments in programmable 
nanoparticles and hydrogels as the primary means of delivery. We have specifically highlighted 
approaches that target cancer and bacterial infections; however, it should be reiterated that many of 
these approaches are nonspecific and can be easily adjusted for other conditions and diseases by 
simply changing the drug of choice or associated biomarkers. 
3.1 Multi-functional therapies 
The beneficial effect of combinatorial and repeated chemotherapy has been known since the 
1960s, when it was first used to treat acute lymphoblastic leukaemia. While highly effective, one of 
the biggest concerns of combinatorial therapy is the systemic cytotoxicity56. Initial research in the 
biomaterials field generally adapted existing materials approaches in order to more efficiently 
coordinate the delivery of multiple therapeutics. For instance, in 2005 Sengupta and colleagues 
developed a system termed “nanocells” for sequential drug delivery to improve cancer treatments57. 
These nanocells consisted of a pegylated-phospholipid block-copolymer envelope that encapsulated 
combretastatin and a nuclear nanoparticle made of poly(lactic-co-glycolic) acid (PLGA) conjugated 
with doxorubicin (Dox). Following accumulation in the tumour via the EPR effect, combretastatin 
was released within 12 hours and promoted the collapse of the vasculature. Meanwhile Dox was 
conjugated to PLGA, which gave rise to a release profile that extended over 15 days. Since Dox-
PLGA is only bioactive as small fragments, this strategy delayed the temporal activation of Dox 
relative to combretastatin. When comparing similar dosages, in vivo experiments revealed that 
nanocells resulted in a significant decrease in the size of tumours compared to no treatment, 
nanocells with just Dox or combretastatin, and simultaneous systemic injections.  
More recently, Lee and colleagues demonstrated that inhibition of epidermal growth factor 
receptor (EGFR) by erlotinib reprograms cells from triple-negative breast cancer and non-small cell 
lung cancer to be more susceptible to death by DNA damage. Subsequent treatment with Dox 24 
hours after erlotinib results in dramatically more cell death than simultaneous delivery or delivery 
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staggered by only one hour58. These results provide compelling evidence that not only are the drugs 
being delivered important, but also the release times and sequence of therapies. In order to take 
advantage of this effect, Morton and colleagues designed a liposome-based system that initially 
released erlotinib with first-order release kinetics (80% released at 50 hours), followed by a slower 
linear release of Dox (35% released at 50 hours)59 (Figure 2). These liposome systems were further 
functionalized with folate to improve in vivo targeting, since folate receptors are upregulated in 
numerous cancers including ovarian carcinomas, endometrial carcinomas, and certain prostate 
cancers60. In vivo studies with xenograft-bearing NCR nude mice found increased shrinkage of 
tumours compared to liposomes loaded with only Dox. 
Another recent report explored the development of a layer-by-layer nanoparticle to 
synergistically block MAPK and PI3K61, two cellular signaling pathways that have significant 
crosstalk and feedback and can enable signaling associated with drug resistance. In this study, the 
authors delivered selumetinib (to block Mek1/2) and PX-866 (to inhibit PI3K) as a means to treat a 
triple-negative breast cancer cell line and a lung cancer cell line possessing a RAS mutation, 
determining that delivery via nanoparticles increased cancer cell death over treatment with just free 
drug.  
In 2011, von Maltzahn and colleagues reported on an interesting nanoparticle system that 
recruits complimentary nanoparticles by using the signalling cascade of targeted cells as the means 
of interaction62. They devised a two-component nanoparticle system where the first nanoparticle 
activates a coagulation cascade locally in a tumour followed by a second nanoparticle that recognizes 
fibrin and targets the enzymatic activity during coagulation. Activation of the coagulation cascade is 
achieved either through the use of gold nanorods, which can be heated using NIR light, or tumour-
targeting human protein tissue factor (tTF-RGD), which induces coagulation by binding to the 
angiogenic αvβ3 receptor. After confirmation of coagulation, the team delivered Dox-loaded 
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liposomes with fibrin-binding peptides and coagulation transglutaminase FXIII to ensure homing 
towards the coagulation regions.  
Another method of enhancing multi-functionality of nanoparticles is by adding coatings that 
interact with cancer cell-specific membrane receptors. Hyaluronic acid is especially suitable in this 
regard as it is a natural receptor of CD44 63, which is upregulated in a variety of cancers, rapidly 
degradable, and easily modified to form hydrogels that respond to changes in environment64. In one 
approach, Jiang et al. developed a system consisting of a TRAIL-loaded hyaluronic acid-based outer 
shell and Dox-loaded liposome based inner shell, which was further modified with the cell 
penetrating peptide R8H365. Upon arrival at the tumour, the nanoparticle’s outer shell rapidly 
degrades due to hyaluronidase, releasing TRAIL and thus triggering the caspace-3 signalling 
pathway involved in programmed cell death. Following this, the inner liposome breaks down to 
release Dox. This system of sequential delivery showed synergistic effects when tested on MDA-
MB-231 cells in vitro and MDA-MB-231 xenograft mouse models in vivo. 
3.2 Nucleotide-based approaches 
Many groups have explored responsive nucleotide approaches for treating cancer that aim to 
ensure the drug will be released via a stimulus inside the target cell. Sun and colleagues have 
developed a self-degradable DNA and anticancer drug delivery system for Dox66. The nanoparticle, 
termed a nanoclew, is composed of folic acid conjugated to DNA with electrostatically bound Dox 
and positively charged DNase nanocapsules. The nanocapsules consist of a polymeric shell with 
acid-sensitive cross linkers that prevent DNase from being released at physiological pH. However, 
when the particles are taken up by cancer cells and enter the endolysosome, the polymer shell 
degrades due to the low acidity, releasing the DNase. The DNase then breaks down the DNA 
backbone of the nanoclew particle, in turn releasing the electrostatically bound Dox. 
Another approach has been developed by the Artzi group and uses RNA nanoparticles that 
target specific mRNA sequences67,68. In one example, the Artzi group attached antisense DNA 
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hairpins to gold nanoparticles46. The hairpins were complimentary to the mRNA sequence of 
multidrug resistance protein 1 (MRP1) and contained intercalated 5-fluorouracil (5-FU) within the 
double helix (Figure 3). The functionalized nanoparticles were placed inside an injectable hydrogel 
to facilitate localized delivery and retention of the therapeutic nanoparticles to specific tumour 
locations in an orthotopic breast cancer mouse model using MDA-MB-231 triple negative breast 
cancer cells. Upon delivery, cells took up the functionalized gold nanoparticles, and if MRP1 mRNA 
was present, the hairpins hybridized with the mRNA to silence it and promote the release of 5-FU. 
Results from the in vivo testing showed a decrease in tumour size of approximately 90%, along with 
significant silencing of MRP1.  
Other groups have also explored using nucleic acids as targeting vectors. Aptamer-siRNA 
chimeras have shown great promise in targeted delivery of siRNA into cells for a variety of diseases 
including cancer69–71 and HIV72–74. These systems have two levels of specificity, the aptamer antigen 
and the siRNA target. Thus, this bimodal targeting strategy requires cells to possess both the ligand 
for the aptamer and the target mRNA for siRNA interference. In the context of prostate cancer, 
chimeras have been developed that bind to prostate-specific membrane antigen (PSMA)75. In vitro 
studies have shown increased cellular uptake and decreased cell viability for PSMA expressing cell 
lines, while in vivo studies with nude mice have shown decreases in tumour size for only tumours 
that express PSMA. Other groups have investigated DNA-protein chimeras, which work in a similar 
manner albeit with the minor change of delivering a protein rather than siRNA76,77. Ultimately, these 
chimera models can be adapted for conjugation onto nanoparticles or hydrogels for more specific and 
localized delivery and potentially can be used to deliver other noncoding RNA such as miRNA, 
circRNA, or lncRNA.  
Along with using nucleic acids to enhance or reduce protein expression, they can also be used 
as binding sites in order to “refill” depots with a drug of interest. Employing hydrogels as drug 
depots coupled with aptamers as drug-binding sites offers a promising delivery approach. Brudno 
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and colleagues recently pioneered the use of refillable hydrogels containing either specific nucleotide 
sequences 78 or click chemistry groups 27 that can bind drugs modified with the complementary 
binding partner (Figure 4). These hydrogel depots concentrate free drug to a specific area, in turn 
achieving high local concentration while mitigating potential off target effects endemic to systemic 
delivery. Furthermore, the ability to reload these systems minimizes the need for numerous medical 
interventions, which in many cases may necessitate surgery. This platform, while initially studied as 
a drug delivery system for tumours, has vast appeal in a wide variety of contexts including bacterial 
infections, drug eluting stents, and osteoarthritis where either concentrated, but localized release of 
drugs is critical or accessibility to the target location is problematic79.  
From the point of programmable nucleotide platforms, treatment of infectious diseases and 
cancer shares many similarities. With the recent rise in antibiotic resistance, localized targeting, 
combinatorial therapies, and consistent delivery will help to extend the useful life of different 
antibiotics and prevent the outbreak of antibiotic-resistant bacteria such as MRSA, PRSP, and MDR 
P. aeruginosa80,81. In this respect, functional nucleotides have the ability to combine multiple 
strategies and approaches in order to effectively eliminate bacteria. Although selectively targeting 
bacteria necessitates a different set of objectives and targets than targeting cancer cells, recent 
research highlighting the importance of minimizing the impact antibiotics have on the natural 
microbiome justifies the development of more effective and precise therapies82,83.  
Similar to the previously delineated drug depot approach, nucleotide-based approaches have 
shown great promise in both delivering localized therapies and controlling bacteria-specific drug 
release. Zhang and colleagues have developed oligonucleotide-functionalized hydrogels that can act 
as both loading and release sites for antibiotics84. Using tetracycline and two separate nucleotide 
sequences they measured a large increase in antibiotic uptake with only a slight increase in release 
time, which they attribute to using oligonucleotides with low affinities. Compared to hydrogels with 
no oligonucleotides, they delayed the formation of E. coli colonies by 24 hours. Importantly, the 
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refilled hydrogels exhibited comparable release profiles to new hydrogels, allowing for localized 
uptake and release of antibiotics over multiple iterations. 
Using a similar nucleotide approach, Kavruk and colleagues have developed aptamer-gated 
mesoporous silica nanoparticles loaded with vancomysin85, which they have termed NanoKeepers86. 
The aptamers blocked the pores and only opened when they bound the target molecule on the surface 
of the target bacteria, in this case S. aureus. Compared to S. epidermidis, which does not express the 
same aptamer antigens, S. aureus showed a 15-fold decrease in minimum inhibitory concentration. 
As expected, there was a consistent decrease in CFUs for 24 hours from 10^3/mL to slightly below 
100/mL. This is compared to a final CFU count of 10^9/mL after 24 hours of unchecked growth. 
While this approach is not explicitly stated as refillable, these nanoparticles can be easily localized 
and reloaded using additional aptamers or click chemistries without losing their efficacy or potency. 
From a broader perspective, the literature is still scarce in this field and to our knowledge 
only one other group has developed an aptamer-NP approach for antibiotic release87. Considering the 
wide range of known aptamers that target bacteria88–90 and recent developments in targeting cancer 
cells (previously described), there is the potential to develop new treatment options for a variety of 
pathogens that have been stubborn or immune to more traditional therapies.  
3.3 Click Chemistry 
 As was highlighted earlier, drug depots can be used with either aptamers or click sites as 
targeted binding sites for drug reloading. Similarly, many of the examples previously outlined can 
also be modified for use with click chemistry. Historically, click chemistries have been employed for 
synthesizing cancer therapies and nanoparticles themselves91, however only recently have they been 
used as a mechanism by which therapies can be made to responsively adapt dynamically to changes 
in the cancer microenvironment.  
 While the advent of copper-free click chemistry enabled in vivo experiments, the ability to 
generate azides in vivo through metabolic labelling has opened a promising avenue to further explore 
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new therapies. The Bertozzi group has developed synthetic azidosugars that can be used to modify 
cell surfaces in vivo92–94. One sugar in particular, tetraacetylated N-azidoacetyl-d-mannosamine 
(Ac4ManNAz), has been used to localize azides on cell surfaces in vivo via an interaction with sialic 
acids on the cell membrane95. A drug with cyclooctyne moieties is then injected to react with the 
azides on the cell surface in vivo with rapid kinetics, ensuring the click reactions occur before 
metabolic clearance will flush out the drug (Figure 4). 
Using this approach, Kim and colleagues have been able to develop a therapy targeting lung 
cancer cells96,97. Initially, chitosan nanoparticles loaded with Ac4ManNAz were injected into 
tumour-bearing mice and taken up at the site of the tumour via the EPR effect97. Once in the cytosol, 
the Ac4ManNAz generated azides on the cell surface as described previously. A second chitosan 
nanoparticle, this time surface-functionalized with bicyclo[6.1.0]nonyne (BCN) and loaded with 
photosensitizer chlorine e6, was then injected intravenously. BCN then underwent a click reaction 
with the azides on the surface, leading to specific uptake and enabling subsequent phototherapy. This 
strategy offers a particular advantage over antigen-based targeting since click reactions are not 
receptor limited and a significant amount of azides can be generated on the cell membrane. 
In the context of bacterial infections, click chemistry approaches for polymer coatings have 
gained headway as promising strategies for contact killing and/or fouling resistance98. Shakiba and 
colleagues have developed a dual orthogonal click reaction approach that allows for highly 
customizable surface modifications for subsequent small molecule and peptide immobilization99. 
They initially designed a set of “adsorbate” structures that bind to gold surfaces with an azide group 
on the terminal end. They then synthesized a middle molecule, a maleimide-terminated alkyne 
composed of two click groups. The alkyne reacts with the azide on the surface while the maleimide 
group performs another click addition with thiols via thiol-Michael addition, in this case cysteine-
terminated poly(L-lysine). Due to the wide variety of click reactions, this strategy of using a dual 
click-functionalized “intermediary” molecule allows for adaptable surfaces that can offer the 
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advantages of orthogonal reactions without having to change the surface chemistry of the biomaterial 
in vivo, often a much harder issue to overcome, while still having flexibility with the antimicrobial 
strategy. 
3.4 Biomaterials for Cell Recruitment 
 Taking a different approach, groups have also looked at using programmable biomaterials to 
deliver specific stimuli to modulate the behaviour of cells in vivo. While many of the examples 
previously expounded can fall in this category, the focus here is to delineate strategies where the cell 
will become the therapeutic agent rather than a small molecule drug, a nucleic acid, or nanoparticle.  
The pioneering work by the Mooney Lab on programmable vaccines to fight cancer was one 
of the first systems to employ a cell recruitment strategy100,101. These approaches look at modulating 
dendritic cells by 1) recruiting cells in an engineering biomaterial using cytokines, 2) presenting the 
antigen of interest to the cells, and 3) releasing them back into the environment to target the tumour. 
More recently, they demonstrated that injectable hydrogels loaded with mesoporous silica rods 
spontaneously self-assemble into a 3D microenvironment that allows for cells to migrate through the 
pores between rods32. It was found that the high aspect ratio of these rods results in many 
CD11c+ dendritic cells being recruited to the site of injection. The hydrogel was also loaded with 
granulocyte-macrophage colony-stimulating factor (GM-CSF), unmethylated cytosine-phosphate-
guanine oligonucleotide (CpG-ODN) sequence, and Ovalbumin (OVA). This combination treatment 
recruits and stimulates dendritic cell growth, programs them to respond to a specific Toll-like 
receptor (TLR9), and then modulates downstream effects in draining lymph nodes, specifically by 
promoting the maturation of B cells.  
 Other strategies have sought to program cells using light as a physical stimulus. TT Lee et al. 
have designed a light-triggered system to selectively activate caged	arginylglycylaspartic acid (RGD) 
in hydrogels to modulate inflammation102. While light-triggered RGD release had previously been 
studied103, this new approach has demonstrated great spatial and temporal control, thus allowing the 
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group to finely control inflammation and vascularization following implantation of a non-fouling 
hydrogel. Upon activation of RGD via UV light, numerous neutrophils (NIMP-R14+) and 
macrophages (CD68+) were seen present near the hydrogel. Interestingly, this study was able to 
directly compare the temporal effect of RGD on a single platform, showing that delayed release of 
RGD leads to less fibrosis and vascularization. 
4. Conclusion and Outlook 
 In this review, several examples of programmable biomaterials that exhibit both dynamic and 
temporal modalities have been highlighted as the next generation of strategies for treating complex 
diseases. The ability to evolve concomitantly with the disease and offer multi-pronged treatment 
options provides researchers, clinicians, and patients with more effective therapeutics and new 
capabilities.  
Certain outstanding challenges must still be addressed both from an engineering and 
biological perspective. From the perspective of delivery platforms, nanoparticle-based approaches 
still predominantly rely on the EPR effect104. While this has distinct advantages, it is a largely 
passive process that has fundamental limits of efficacy, including reliance on vascularization, the 
relatively rapid rate of clearance by the renal system, and potential immune response from long term 
treatments. Hydrogels, on the other hand, are able to circumvent some of these issues due to their 
ability to be placed near the site of interest and locally deliver drugs over a prolonged period of 
time105,106. Further research is necessary to both determine what biological markers are appropriate 
for developing responsive elements and the effectiveness of that response. We envision that such 
materials may identify sudden changes to tumor or bacterial environments and deliver the 
appropriate drug without the need for clinical intervention. 
Recent years have shown an ever expanding toolbox of technologies at researchers’ and 
clinicians’ disposal107,108. At the same time, further work is still necessary to continue this positive 
trend. For example, oligonucleotide approaches are still largely one dimensional in their uses (e.g. 
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react to a stimulus to release a drug). Due to the simplicity of oligonucleotides and their ability to be 
readily incorporated onto virtually any platform, future systems may strive towards increasing 
multifunctionality (e.g. theranostic capabilities coupled with readouts of efficacy). While researchers 
have begun to use biological moieties, we believe that there is still great potential to further expand 
this approach. For example, the approaches outlined for cell recruitment100 and using biological 
cascades to achieve better drug delivery62 are innovative and potentially promising strategies.  
Ultimately, the success and justification of these therapies will hinge on their ability to not 
only surpass systemic therapies, but also the advantages of previous generations of nanomedicine. In 
the end it is the ability to engineer interactions between materials and cells to be a bidirectional 
feedback system, one that is able to actively adapt and transform in response to cellular changes, that 
will unlock new potential for treating the most stubborn of diseases.  
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Figure Captions 
 
Figure	1.	There	are	a	variety	of	enabling	technologies	that	underlie	the	ability	to	program	functionality	into	
therapeutic	materials.	(a)	Click	chemistry	reactions	are	convenient	for	their	high	reaction	efficiency,	bio-
orthogonality,	specificity,	and	low	toxicity.	The	stereotypical	click	reaction	is	the	Cu-catalysed	alkyne-azide	
reaction,	although	the	Cu	catalyst	can	present	toxicity	problem	in	vivo.	Other	click	reactions	such	as	the	one	
between	an	azide	and	dibenzocyclooctyne	(DBCO)	do	not	require	Cu	catalysts,	instead	being	catalysed	by	the	
ring	strain	present	in	the	cyclooctyne.	(b)	Nucleic	acids	provide	an	additional	avenue	for	programming	
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functionality	into	materials.	Aptamers	can	be	used	both	for	targeting	overexpressed	proteins	on	cell	surfaces	
and	as	a	therapeutic.	(c)	Finally,	the	breakdown	and	release	of	materials	is	tuneable	by	using	enzyme	
degradable	sequences,	such	as	those	that	are	substrates	for	MMPs.	
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Figure	2.	a).	Morton	and	colleagues	have	designed	a	liposome	to	target	cancer	cells	and	stagger	the	release	
of	encapsulated	therapeutics59.	In	this	case,	folate	conjugated	to	the	surface	of	liposomes	promoted	
enhanced	binding	by	triple-negative	breast	cancer	cells.	Erlotinib	loads	into	the	core	of	the	lipid	bilayer	due	
to	its	hydrophobic	nature,	while	Dox	loads	into	the	aqueous	vesicle	core.	(b)	This	arrangement	of	
therapeutics	allows	for	the	initial	release	of	erlotinib,	followed	by	a	slower	release	of	Dox.	Using	this	specific	
sequence	of	therapy	results	in	the	rewiring	of	cancer	cells	to	make	them	more	susceptible	to	DNA	damage,	
dramatically	increasing	the	efficacy	of	this	combination	of	drugs.				
	
	
Figure	3.	Nanoparticles	have	been	developed	that	contain	DNA	antisense	oligonucleotide	hairpins	
conjugated	to	gold	nanoparticles.	5-FU	can	then	be	loaded	within	the	double	helix	of	the	hairpins.	Following	
entry	into	cancer	cells,	the	DNA	hairpins	hybridize	with	and	silence	the	mRNA	associated	with	5-FU	drug	
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resistance	while	simultaneously	releasing	the	bound	5-FU.	This	strategy	has	been	shown	to	significantly	
increase	effectiveness	of	5-FU	on	5-FU	resistant	cancer	cells46.		
	
	
Figure	4.	Click	chemistry	has	been	used	to	concentrate	systemic	drugs	at	the	site	of	interest27,97,	which	can	
be	accomplished	in	several	ways.	(Top)	Hydrogels	functionalized	with	a	molecule	such	as	DBCO	can	be	
injected	into	a	localized	tissue	site.	Subsequent	injection	with	azide-tagged	therapeutics	enables	
concentration	at	the	hydrogel	site	via	the	click	reaction.	(Bottom)	Cells	can	also	be	labelled	with	azide	groups	
to	directly	target	the	cells	themselves.	Subsequent	injection	with	therapeutics	labelled	with	the	
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complimentary	click	group,	in	this	case	DBCO,	results	in	concentration	at	the	membranes	of	the	cells	
expressing	azides	followed	by	subsequent	uptake.			
 
